What is the address of ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND?

The registered office of ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND is located at Brusselsesteenweg 11, 1860 Meise.

Is ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND still active?

Yes. According to the CBE (29 October 2026) ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND is active, legal situation “Normale toestand”, started on 21 June 2013.

Is ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND registered on Peppol?

Yes, ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND is registered on the Peppol network with ID 0208:0535868481.

Is ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 21 June 2013; 5 annual accounts filed, latest fiscal year 2025; 6 directors known from the annual account.

What is the revenue of ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND?

As a small company, ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,990,711.

How much does an employee at ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND earn?

The average wage cost per full-time employee at ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND was € 122,300 in 2025: staff costs of € 1.4 million for 11.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND - Meise

Q: What does ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND do?

ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND is filed with the CBE under the catch-all “Verenigingen op het vlak van ziektepreventie en gezondheidsbevordering”, a code that says little about what the company actually does. Public Foundation, started on 21 June 2013, 1 establishment.

Q: What is the enterprise number of ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND?

The enterprise number of ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND is BE0535868481.

Q: When was ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND founded?

ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND was founded on 21 June 2013.

Q: Who are the directors of ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND?

According to the 2025 annual accounts, the directors of ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND are: Alice DOSSCHE, Luc TAYART de Borms, Lydie MEHEUS, Rudy DEKEYSER, Luc VERELST, Johan VAN BIESBROECK.

Q: How much profit did ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND make in 2025?

ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND posted a profit after taxes of € 584,413 in financial year 2025.

Dossier ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND, printed on 29 October 2026 from databakkes.be/en/0535868481/antikankerfonds-fonds-anticancer-anticancer-fund. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND from Meise, company number BE0535868481, closed financial year 2025 with a result of € 584,413 after tax. For that financial year ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND recorded a gross margin of € 2 million and equity of € 5.3 million. Compared with financial year 2024, the result moved from € 233,594 to € 584,413. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.

What it is worth Growing

€ 5.3 million

▲ 17% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 584,413

▲ 150% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 2.7 million

▲ 84% vs 2024

Cash and bank balances on the last day of the fiscal year.

People and assets in 2025

Full-time equivalents

11.4

▲ 1.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 1.4 million

▲ 5% vs 2024

€ 122,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 8,117

▲ 2% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 11,990

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 46,013

▼ 37% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 228,349

▲ 15% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 9,863 Gross margin 2022: € 9,863 First fiscal year in the series	€ 1,625,529 Gross margin 2023: € 1,625,529 ▲ € 1.6 million vs 2022 (€ 9,863) Favourable step	€ 1,550,109 Gross margin 2024: € 1,550,109 ▼ 5% vs 2023 (€ 1,625,529) Unfavourable step	€ 1,990,711 Gross margin 2025: € 1,990,711 ▲ 28% vs 2024 (€ 1,550,109) Favourable step	▲ 28%
Profit after taxes	€ -998,894 Profit after taxes 2022: € -998,894 First fiscal year in the series	€ 443,432 Profit after taxes 2023: € 443,432 ▲ € 1.4 million vs 2022 (€ -998,894) Favourable step	€ 233,594 Profit after taxes 2024: € 233,594 ▼ 47% vs 2023 (€ 443,432) Unfavourable step	€ 584,413 Profit after taxes 2025: € 584,413 ▲ 150% vs 2024 (€ 233,594) Favourable step	▲ 150%
Equity	€ 3,865,764 Equity 2022: € 3,865,764 First fiscal year in the series	€ 4,309,196 Equity 2023: € 4,309,196 ▲ 11% vs 2022 (€ 3,865,764) Favourable step	€ 4,542,790 Equity 2024: € 4,542,790 ▲ 5% vs 2023 (€ 4,309,196) Favourable step	€ 5,318,167 Equity 2025: € 5,318,167 ▲ 17% vs 2024 (€ 4,542,790) Favourable step	▲ 17%
Total debts	€ 240,261 Total debts 2022: € 240,261 First fiscal year in the series	€ 279,073 Total debts 2023: € 279,073 ▲ 16% vs 2022 (€ 240,261) Unfavourable step	€ 293,419 Total debts 2024: € 293,419 ▲ 5% vs 2023 (€ 279,073) Unfavourable step	€ 667,513 Total debts 2025: € 667,513 ▲ 127% vs 2024 (€ 293,419) Unfavourable step	▲ 127%
Cash	€ 3,673,782 Cash 2022: € 3,673,782 First fiscal year in the series	€ 1,774,176 Cash 2023: € 1,774,176 ▼ 52% vs 2022 (€ 3,673,782) Unfavourable step	€ 1,484,063 Cash 2024: € 1,484,063 ▼ 16% vs 2023 (€ 1,774,176) Unfavourable step	€ 2,724,558 Cash 2025: € 2,724,558 ▲ 84% vs 2024 (€ 1,484,063) Favourable step	▲ 84%
Land & buildings	-	-	-	€ 581,613 Land & buildings 2025: € 581,613 First fiscal year in the series
Retained profit	€ 3,865,764 Retained profit 2022: € 3,865,764 First fiscal year in the series	€ 4,309,196 Retained profit 2023: € 4,309,196 ▲ 11% vs 2022 (€ 3,865,764) Favourable step	€ 4,542,790 Retained profit 2024: € 4,542,790 ▲ 5% vs 2023 (€ 4,309,196) Favourable step	€ 5,127,203 Retained profit 2025: € 5,127,203 ▲ 13% vs 2024 (€ 4,542,790) Favourable step	▲ 13%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 11,990 Bank debt 2025: € 11,990 Unchanged (€ 0) Unfavourable step
Balance sheet total	€ 4,106,025 Balance sheet total 2022: € 4,106,025 First fiscal year in the series	€ 4,588,269 Balance sheet total 2023: € 4,588,269 ▲ 12% vs 2022 (€ 4,106,025) Unchanged	€ 4,836,209 Balance sheet total 2024: € 4,836,209 ▲ 5% vs 2023 (€ 4,588,269) Unchanged	€ 5,985,679 Balance sheet total 2025: € 5,985,679 ▲ 24% vs 2024 (€ 4,836,209) Unchanged	▲ 24%
Employees (FTE)	8.7 Employees (FTE) 2022: 8.7 First fiscal year in the series	9.7 Employees (FTE) 2023: 9.7 ▲ 1 vs 2022 (8.7) Unchanged	10.2 Employees (FTE) 2024: 10.2 ▲ 0.5 vs 2023 (9.7) Unchanged	11.4 Employees (FTE) 2025: 11.4 ▲ 1.2 vs 2024 (10.2) Unchanged	▲ 1.2

Key figures of ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND?

What happened at ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 17, 2026 New annual accounts for financial year 2025: profit of € 584,413 (▲ 150% vs 2024). Source: NBB ↗
2025 Johan VAN BIESBROECK stepped down as director. NBB
2022 Alice DOSSCHE became a director. NBB
2022 Luc TAYART de Borms became a director. NBB
2022 Rudy DEKEYSER became a director. NBB
2015 Johan VAN BIESBROECK became a director. NBB
Jun 21, 2013 New establishment in Meise. KBO
Jun 21, 2013 Start of the company according to the CBE. KBO

In short

From € 998,894 loss in 2022 to € 584,413 profit in 2025.

Paid € 65,274 in corporate taxes since 2022.

Best year ever: 2025, with € 584,413 profit.

On average € 174,600 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Alice DOSSCHE Luc TAYART de Borms Lydie MEHEUS Rudy DEKEYSER +1

Journalismfund Europe

ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND

reMYND

R.A.D. LIFE SCIENCES

Behind ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND are Alice DOSSCHE, Luc TAYART de Borms, Lydie MEHEUS, Rudy DEKEYSER and Luc VERELST. Luc TAYART de Borms is also behind Journalismfund Europe. Rudy DEKEYSER is also behind reMYND, R.A.D. LIFE SCIENCES, Health Economics Privak II, LSP 6 Privak and LSP 7 Privak.

Directors

According to the 2025 annual accounts

Alice DOSSCHE

Director

since 2022

Luc TAYART de Borms

Director

Also active at: Journalismfund Europe

since 2022

Lydie MEHEUS

Managing director

since 2013

Rudy DEKEYSER

Director

Also active at: reMYND, R.A.D. LIFE SCIENCES, Health Economics Privak II, LSP 6 Privak, LSP 7 Privak, EQT Partners Belgium, Fondation Fournier Majoie pour l'Innovation, EQT Health Economics 3 Privak +1 more

since 2022

Luc VERELST

Director

Also active at: PROBEC

since 2013

Johan VAN BIESBROECK

Director

Also active at: Fondation KickCancer

since 2015 · until 2025

Establishments

Establishment units

Physical locations of this company

Registered office

Brusselsesteenweg 11

1860 Meise

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0535.868.481

VAT number

BE 0535.868.481

Registered office

Brusselsesteenweg 11, 1860 Meise

Names & denominations

ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND

Enterprise type

Rechtspersoon

Legal form

Public-interest foundation

Legal situation

Normale toestand

Start date

21 June 2013

Peppol

Active · Active since 23 Oct 2025

Activities · NACE

Verenigingen op het vlak van ziektepreventie en gezondheidsbevordering

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Overige gespecialiseerde wetenschappelijke en technische activiteiten

View on CBE Public ↗ Annual accounts (NBB) ↗

ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND

Financials

What happened to ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions